TB-500: what the research actually says

TB-500 almost never appears on its own. It's usually mentioned in the same breath as BPC-157, marketed as a recovery "stack" for injuries. As with BPC-157, the marketing has outrun the science considerably, and it's worth separating what is known from what is assumed.

What TB-500 is

TB-500 is sold as a synthetic version of a specific fragment of Thymosin Beta-4 (often written Tβ4) — specifically amino acids 17 through 23 of the parent protein, chemically written as Ac-LKKTETQ. This makes it a seven-amino-acid synthetic heptapeptide, not the full protein itself.

Thymosin beta-4 is a naturally occurring 43-amino-acid protein found in nearly every human and animal cell, where it is involved in actin binding, cell movement, blood vessel formation, and wound repair.² It's important to understand a distinction that gets systematically blurred in marketing: most of the published research is on native thymosin beta-4 or lab-engineered thymosin-beta-4 variants — not on an identical product to what's sold commercially as "TB-500." The two get treated as interchangeable routinely; they are not.

What the evidence shows — and where it stops

Recent peer-reviewed studies on thymosin beta-4 and its engineered variants are almost entirely preclinical: cell-culture and animal models of diabetic wound healing, corneal repair, and fat-graft survival.² These are legitimate, published findings, but they describe what happens in mice, rats, or lab dishes — not in people.

There are essentially no published controlled human clinical trials of TB-500 specifically establishing that it speeds healing, improves recovery, or is safe at any dose in humans. As with most peptides in this category, "shows an effect in a rodent wound model" and "shown to work in people" are two very different claims, and only the first is currently supported by data.

What thymosin beta-4's clinical trial record actually shows

This is where the picture gets both more informative and more sobering. The full protein — thymosin beta-4 — has a genuine, documented development history. As of mid-2026, there are 17 registered human studies on ClinicalTrials.gov going back to February 2006, with 2,121 participants enrolled across four indication areas: wound healing, dry eye syndrome, neurotrophic keratopathy (a rare corneal disease), and acute myocardial infarction.

Twenty years of trials and 2,121 participants have produced exactly zero FDA approvals. Understanding why matters for anyone evaluating the fragment sold as TB-500.

Corneal disease (neurotrophic keratopathy): The most advanced program used a thymosin beta-4 eye drop, RGN-259, in patients whose corneas cannot heal normally because nerve damage has robbed them of sensation. SEER-1, a Phase 3 trial with 18 subjects, found complete corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo at day 29 — a striking-looking difference that nonetheless produced a p-value of 0.0656 and therefore a statistical miss. SEER-3, a European Phase 3 with roughly 70 patients across sites in Spain, Italy, Poland, and Germany, missed its primary endpoint in July 2026. The company attributed the result to a placebo arm that healed better than anticipated, leaving no room for the drug to show a difference. A second US trial, SEER-2, is still running.

Dry eye syndrome: Three Phase 3 trials with roughly 1,600 participants have been completed. None cleared their primary endpoints. The drug is still not approved for dry eye.

Cardiac repair: Two Phase 2 studies in acute myocardial infarction were completed; neither has posted results on the registry. A fifth trial from the same sponsor was registered in May 2026.

None of these trials tested TB-500 — the seven-amino-acid commercial fragment. They tested the full 43-amino-acid protein. Anyone citing these trials as evidence for the injectable sold online is transferring credibility from a molecule that has been tested to one that has not.

Evidence summary by indication

The metabolite problem

A 2024 study published in the Journal of Chromatography B added a specific wrinkle to the case for TB-500 that has gone largely unremarked in wellness marketing.⁵ The study, designed primarily to help anti-doping laboratories detect TB-500 in samples, tracked what the compound breaks down into in human serum, enzyme systems, and rats.

TB-500 degrades quickly. Ac-LK was the primary metabolite found in rats during the first six hours; Ac-LKK was detectable up to 72 hours. The researchers then screened both the parent compound and its metabolites for wound-healing activity in fibroblast cell assays. The result was not the expected one: Ac-LKKTE — a metabolite, not TB-500 itself — was the only compound that showed significant wound-healing activity compared to control. TB-500 itself did not show significant wound-healing activity in the same assay.

One in-vitro screen is not a verdict, and the authors were appropriately careful about extrapolating. But it points at a real problem with the marketing argument for the fragment. The case for TB-500 has always rested on the idea that this short sequence carries the parent protein's useful biological activity. This study suggests that whatever activity exists in the region may belong to a different short sequence — one that TB-500 has to be metabolized into first — and which no one is currently selling or studying as a standalone compound.

Regulatory status

TB-500 is not an FDA-approved drug for any use. In late 2023, the FDA took a specific regulatory action: it assigned 17 peptides — including TB-500 — to Category 2 bulk drug substance status, a designation meaning they cannot legally be used in pharmaceutical compounding due to safety concerns.¹ This is a harder regulatory position than simply "unapproved" — it means even licensed compounding pharmacies cannot legally prepare TB-500 for patients.

For anything sold online as "research use only," there is no manufacturing oversight, no sterility requirement, no label accuracy requirement, and no requirement that the vial contains what it claims at the concentration it claims, free of contaminants. Pharmacist analyses of unregulated peptide products have found endotoxins, incomplete peptide sequences, residual solvents, and microbial contamination in similar products.

TB-500 vs. BPC-157

The two are frequently stacked together specifically because their marketing claims overlap. Read the dedicated breakdown on BPC-157 for the FDA's 2023 compounding action, which applies to that molecule specifically.

Anti-doping and sports prohibition

TB-500 is listed by the World Anti-Doping Agency on its Prohibited List under category S0 — "Non-Approved Substances" — which means it is prohibited at all times, both in and out of competition.⁶ It is classified as a non-Specified Substance, which carries the harshest sanction tier under the WADA Code.

This is not theoretical. In a documented case, a Canadian athlete received a four-year ineligibility period for use of a stack including TB-500 and BPC-157, both of which sit in the S0 and S2 categories. The U.S. Department of Defense has also formally adopted the WADA Prohibited List categories S0 through S5, which means TB-500 is prohibited for military personnel subject to drug testing. Athletes, military members, and first responders subject to WADA-aligned testing programs face the same compliance risk.

“Unfortunately, there just isn't enough valuable, statistically significant evidence that points us to be able to recommend them safely.”

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, discussing newer injectable peptides marketed for recovery and muscle growth, in the American Medical Association (April 2026)

What's actually known about safety

Because human trials don't exist for TB-500 specifically, there's no established human dosing, no data on drug interactions, and no long-term safety record for the commercial fragment. Whatever is in a specific vial depends entirely on the manufacturer, and "research use only" products carry no verification that the contents match the label. That combination — unverified product plus self-injection with no medical oversight — is where most real-world harm in this category originates, not necessarily from the molecule in isolation.

The broader safety data from thymosin beta-4 trials (the full protein) describes most adverse events as mild and transient. But those observations cannot be reliably extrapolated to the fragment, which is a different compound manufactured without regulatory controls and used without clinical supervision.

Harvard Health Publishing notes that the entire category of injectable peptides sold outside of regulated medical channels represents an area where individuals are essentially running their own uncontrolled experiments, with no systematic collection of outcome data.⁴

If you're considering it anyway

The same guidance applies here as for any unapproved peptide: a licensed clinician can tell you honestly what human evidence does and doesn't exist, and only a licensed pharmacy channel has any quality control at all. For athletes or military personnel, the WADA S0 prohibition means any use carries career-ending sanction risk regardless of outcome. Our safest way to try peptides guide covers how to vet a provider, and our broader peptide safety overview covers the full risk landscape of this category.